NO20052313L - Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av - Google Patents
Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling avInfo
- Publication number
- NO20052313L NO20052313L NO20052313A NO20052313A NO20052313L NO 20052313 L NO20052313 L NO 20052313L NO 20052313 A NO20052313 A NO 20052313A NO 20052313 A NO20052313 A NO 20052313A NO 20052313 L NO20052313 L NO 20052313L
- Authority
- NO
- Norway
- Prior art keywords
- formulation
- nasal administration
- melagatran
- medicament
- aqueous pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SAMMENDRAG En vandig farmasøytisk formulering omfattende trombin-inhibitoren HOOC-CH2-(R)-Cgl- Aze-Pab (melagatran) eller et farmasøytisk akseptabelt derivat derav, en fremgangsmåte for fremstilling av en slik farmasøytisk formulering, anvendelse av en slik formulering ved behandling av tromboembolisme så vel som en metode for behandling av en pasient med behov for antitrombotisk behandling og tromboembolisme ved anvendelse av nevnte formulering via nasal administrering.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203349A SE0203349D0 (sv) | 2002-11-12 | 2002-11-12 | New use |
PCT/SE2003/001738 WO2004043486A1 (en) | 2002-11-12 | 2003-11-11 | An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20052313L true NO20052313L (no) | 2005-06-06 |
Family
ID=20289548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052313A NO20052313L (no) | 2002-11-12 | 2005-05-11 | Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060014699A1 (no) |
EP (1) | EP1581255A1 (no) |
JP (1) | JP2006507323A (no) |
KR (1) | KR20050074598A (no) |
CN (1) | CN1711104A (no) |
AU (1) | AU2003276801A1 (no) |
BR (1) | BR0316123A (no) |
CA (1) | CA2504480A1 (no) |
MX (1) | MXPA05005118A (no) |
NO (1) | NO20052313L (no) |
SE (1) | SE0203349D0 (no) |
WO (1) | WO2004043486A1 (no) |
ZA (1) | ZA200503711B (no) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050153946A1 (en) * | 2003-12-24 | 2005-07-14 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US7345093B2 (en) * | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
EP2480208A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes |
US20110070294A1 (en) * | 2009-09-23 | 2011-03-24 | Javeri Indu | Methods for the Administration of Drugs Using Liposomes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984627B1 (en) * | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
SE9404196D0 (sv) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
SE9602145D0 (sv) * | 1996-05-31 | 1996-05-31 | Astra Ab | New improved formulation for treatment of thromboembolism |
SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
AR023510A1 (es) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
GB0014134D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
-
2002
- 2002-11-12 SE SE0203349A patent/SE0203349D0/xx unknown
-
2003
- 2003-11-11 WO PCT/SE2003/001738 patent/WO2004043486A1/en not_active Application Discontinuation
- 2003-11-11 US US10/533,869 patent/US20060014699A1/en not_active Abandoned
- 2003-11-11 AU AU2003276801A patent/AU2003276801A1/en not_active Abandoned
- 2003-11-11 BR BR0316123-4A patent/BR0316123A/pt not_active IP Right Cessation
- 2003-11-11 CN CNA2003801030983A patent/CN1711104A/zh active Pending
- 2003-11-11 MX MXPA05005118A patent/MXPA05005118A/es unknown
- 2003-11-11 JP JP2004551332A patent/JP2006507323A/ja active Pending
- 2003-11-11 KR KR1020057008436A patent/KR20050074598A/ko not_active Application Discontinuation
- 2003-11-11 EP EP03811169A patent/EP1581255A1/en not_active Withdrawn
- 2003-11-11 CA CA002504480A patent/CA2504480A1/en not_active Abandoned
-
2005
- 2005-05-09 ZA ZA200503711A patent/ZA200503711B/en unknown
- 2005-05-11 NO NO20052313A patent/NO20052313L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA05005118A (es) | 2005-07-01 |
WO2004043486A1 (en) | 2004-05-27 |
SE0203349D0 (sv) | 2002-11-12 |
US20060014699A1 (en) | 2006-01-19 |
CN1711104A (zh) | 2005-12-21 |
JP2006507323A (ja) | 2006-03-02 |
AU2003276801A1 (en) | 2004-06-03 |
WO2004043486A8 (en) | 2005-03-17 |
ZA200503711B (en) | 2006-11-29 |
KR20050074598A (ko) | 2005-07-18 |
CA2504480A1 (en) | 2004-05-27 |
EP1581255A1 (en) | 2005-10-05 |
BR0316123A (pt) | 2005-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO972475L (no) | Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav | |
NO20063373L (no) | CD40-antistoff-formuleringer og fremgangsmater | |
IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
NO20060416L (no) | Ny anvendelse I | |
NO20060974L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
NO20050948L (no) | Preparater med langvarig frigivelse omfattende lamotrigin | |
BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
CY1110289T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια ρινιτιδων | |
SE0102276D0 (sv) | Device and method for the administration of a medicament | |
DK0833643T3 (da) | Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme | |
DK1546127T3 (da) | Nye pyrimidinamidderivater og anvendelse deraf | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
NO20052313L (no) | Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av | |
DE60220055D1 (de) | 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden | |
CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
NO20013301L (no) | Ny dialysemetode | |
NO962752L (no) | Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose | |
AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
WO2004041191A3 (en) | Methods for the treatment, prevention and management of macular degeneration | |
NO20042758L (no) | Fremgangsmate for behandling av en pasient som krever analgesi. | |
PL368686A1 (en) | Novel aminobenzoephenones | |
AR027394A1 (es) | Uso de mirtazapina para el tratamiento de trastornos del sueno | |
SE0102887D0 (sv) | New formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |